Structures of Immune Checkpoints: An Overview on the CD28-B7 Family

Weifeng Liu, Xingxing Zang

Research output: Contribution to journalReview article

Abstract

The co-stimulation and co-inhibition signal pathways, immune checkpoints, are among the central mechanisms to regulate the T-cell immunity. Optimal signals involve intricate interactions of numerous ligands and receptors. Manipulation of these signals offers great clinical opportunities and has revolutionized the cancer treatment therapies. The 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo in recognition of their discovery of cancer immunotherapy by inhibition of immune checkpoint molecules. Despite the landmark discovery in cancer immunotherapy, the efforts to harness immunity against cancer are also restricted by the limited knowledge on the co-stimulation and co-inhibition signaling networks. Understanding the structures of these molecules, in particular, tackling the interaction paradigms from the structural perspective, help to provide more accurate insights into the signaling mechanisms, which may further facilitate the development of novel biologics and improve the efficacy of the existing biologics against these targets. Here we review our current understanding on the structures of these co-stimulatory and co-inhibitory molecules. Specifically, we focus on the structural basis of several checkpoint molecules among the CD28-B7 family and discuss the therapeutic drugs against these targets for the treatment of human cancers, autoimmune disorders, and transplantation.

Original languageEnglish (US)
Pages (from-to)63-78
Number of pages16
JournalAdvances in experimental medicine and biology
Volume1172
DOIs
StatePublished - Jan 1 2019

Fingerprint

Molecules
Biological Products
Neoplasms
Immunotherapy
Immunity
Oncology
T-cells
Physiology
Nobel Prize
Medicine
Therapeutics
Ligands
Signal Transduction
Transplantation
T-Lymphocytes
Pharmaceutical Preparations

Keywords

  • CD28-B7 family
  • Co-inhibition
  • Co-stimulation
  • Immune checkpoint
  • Immunotherapy
  • Structures

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Structures of Immune Checkpoints : An Overview on the CD28-B7 Family. / Liu, Weifeng; Zang, Xingxing.

In: Advances in experimental medicine and biology, Vol. 1172, 01.01.2019, p. 63-78.

Research output: Contribution to journalReview article

@article{a832542de5e549c48ab4cfa11b98ab1a,
title = "Structures of Immune Checkpoints: An Overview on the CD28-B7 Family",
abstract = "The co-stimulation and co-inhibition signal pathways, immune checkpoints, are among the central mechanisms to regulate the T-cell immunity. Optimal signals involve intricate interactions of numerous ligands and receptors. Manipulation of these signals offers great clinical opportunities and has revolutionized the cancer treatment therapies. The 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo in recognition of their discovery of cancer immunotherapy by inhibition of immune checkpoint molecules. Despite the landmark discovery in cancer immunotherapy, the efforts to harness immunity against cancer are also restricted by the limited knowledge on the co-stimulation and co-inhibition signaling networks. Understanding the structures of these molecules, in particular, tackling the interaction paradigms from the structural perspective, help to provide more accurate insights into the signaling mechanisms, which may further facilitate the development of novel biologics and improve the efficacy of the existing biologics against these targets. Here we review our current understanding on the structures of these co-stimulatory and co-inhibitory molecules. Specifically, we focus on the structural basis of several checkpoint molecules among the CD28-B7 family and discuss the therapeutic drugs against these targets for the treatment of human cancers, autoimmune disorders, and transplantation.",
keywords = "CD28-B7 family, Co-inhibition, Co-stimulation, Immune checkpoint, Immunotherapy, Structures",
author = "Weifeng Liu and Xingxing Zang",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-981-13-9367-9_3",
language = "English (US)",
volume = "1172",
pages = "63--78",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Structures of Immune Checkpoints

T2 - An Overview on the CD28-B7 Family

AU - Liu, Weifeng

AU - Zang, Xingxing

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The co-stimulation and co-inhibition signal pathways, immune checkpoints, are among the central mechanisms to regulate the T-cell immunity. Optimal signals involve intricate interactions of numerous ligands and receptors. Manipulation of these signals offers great clinical opportunities and has revolutionized the cancer treatment therapies. The 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo in recognition of their discovery of cancer immunotherapy by inhibition of immune checkpoint molecules. Despite the landmark discovery in cancer immunotherapy, the efforts to harness immunity against cancer are also restricted by the limited knowledge on the co-stimulation and co-inhibition signaling networks. Understanding the structures of these molecules, in particular, tackling the interaction paradigms from the structural perspective, help to provide more accurate insights into the signaling mechanisms, which may further facilitate the development of novel biologics and improve the efficacy of the existing biologics against these targets. Here we review our current understanding on the structures of these co-stimulatory and co-inhibitory molecules. Specifically, we focus on the structural basis of several checkpoint molecules among the CD28-B7 family and discuss the therapeutic drugs against these targets for the treatment of human cancers, autoimmune disorders, and transplantation.

AB - The co-stimulation and co-inhibition signal pathways, immune checkpoints, are among the central mechanisms to regulate the T-cell immunity. Optimal signals involve intricate interactions of numerous ligands and receptors. Manipulation of these signals offers great clinical opportunities and has revolutionized the cancer treatment therapies. The 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo in recognition of their discovery of cancer immunotherapy by inhibition of immune checkpoint molecules. Despite the landmark discovery in cancer immunotherapy, the efforts to harness immunity against cancer are also restricted by the limited knowledge on the co-stimulation and co-inhibition signaling networks. Understanding the structures of these molecules, in particular, tackling the interaction paradigms from the structural perspective, help to provide more accurate insights into the signaling mechanisms, which may further facilitate the development of novel biologics and improve the efficacy of the existing biologics against these targets. Here we review our current understanding on the structures of these co-stimulatory and co-inhibitory molecules. Specifically, we focus on the structural basis of several checkpoint molecules among the CD28-B7 family and discuss the therapeutic drugs against these targets for the treatment of human cancers, autoimmune disorders, and transplantation.

KW - CD28-B7 family

KW - Co-inhibition

KW - Co-stimulation

KW - Immune checkpoint

KW - Immunotherapy

KW - Structures

UR - http://www.scopus.com/inward/record.url?scp=85073628717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073628717&partnerID=8YFLogxK

U2 - 10.1007/978-981-13-9367-9_3

DO - 10.1007/978-981-13-9367-9_3

M3 - Review article

C2 - 31628651

AN - SCOPUS:85073628717

VL - 1172

SP - 63

EP - 78

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -